Californian protein sequencing company Alamar Biosciences is seeking an IPO worth up to $159 million amid a growing boom in ...

Harbinger Health has grabbed $100 million in its latest funding round as the company reveals a new Resolve in its cancer ...

KAI-7535, a once-daily injectable small-molecule GLP-1, will receive a $50 million boost following the IPO. Hengrui has ...

Retractable Technologies, the maker of a retractable needle and other safety medical products, is cutting roughly 16% of its ...

Spyre Therapeutics’ monoclonal antibody hit the key goal of a phase 2 study in ulcerative colitis (UC), which the company has touted as proof it can best Takeda’s Entyvio. The mid-stage trial ...

An FDA review of records in the U.S. clinical trials database shows that results have not been reported for 30% of clinical ...

AbbVie has agreed to pay $30 million upfront to Haisco Pharmaceutical Group for ex-China rights to two non-opioid pain treatment candidates. | AbbVie has agreed to pay $30 million upfront to Chinese ...

Speaking to Fierce at the European Society for Medical Oncology (ESMO) Congress in Berlin at the time, GSK’s Hesham Abdullah, ...

With its latest obesity play appearing to pay off, Regeneron has turned its attention to radiopharmaceuticals. | With its latest obesity play appearing to pay off, Regeneron has turned its attention ...

Allogene Therapeutics’ gamble on a never-before-seen trial strategy seems to be paying off, with the biotech’s off-the-shelf cell therapy eradicating residual lymphoma in over half of evaluated pat | ...

Revolution Medicines’ pan-RAS inhibitor helped patients with a highly aggressive form of pancreatic cancer live an average of six months longer than chemotherapy, hitting a goal of the phase 3 study.

A phase 2/3 trial of Ideaya Biosciences and Servier’s eye cancer candidate has hit its primary endpoint, teeing up a filing for accelerated FDA approval in the second half of th ...